Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis

Boogaard, Jossy van den; Gier, Brechje de; Lima, Priscila de Oliveira Bressane; Desai, Shalini; Melker, Hester E. de; Hahné, Susan; Veldhuijzen, Irene

doi:10.1016/j.vaccine.2020.12.079

Cited by 11 publications

(15 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although antimicrobial treatments have been shown to improve hearing outcomes for some infections such as toxoplasmosis and syphilis [ 84 , 85 , 86 ], there is no current effective treatment or vaccine for congenital CMV [ 87 , 88 ]. Several groups have proposed that persistent inflammation may be responsible for the worsening of hearing in CMV-infected infants [ 89 , 90 , 91 ].…”

Section: The Cochlea As a Model Organ To Study The Effect Of Early Life Inflammation On The Developing Hematopoietic And Immune Systemsmentioning

confidence: 99%

Early Life Inflammation and the Developing Hematopoietic and Immune Systems: The Cochlea as a Sensitive Indicator of Disruption

Otsuka

Nielson

Firpo

et al. 2021

Cells

View full text Add to dashboard Cite

Emerging evidence indicates that perinatal infection and inflammation can influence the developing immune system and may ultimately affect long-term health and disease outcomes in offspring by perturbing tissue and immune homeostasis. We posit that perinatal inflammation influences immune outcomes in offspring by perturbing (1) the development and function of fetal-derived immune cells that regulate tissue development and homeostasis, and (2) the establishment and function of developing hematopoietic stem cells (HSCs) that continually generate immune cells across the lifespan. To disentangle the complexities of these interlinked systems, we propose the cochlea as an ideal model tissue to investigate how perinatal infection affects immune, tissue, and stem cell development. The cochlea contains complex tissue architecture and a rich immune milieu that is established during early life. A wide range of congenital infections cause cochlea dysfunction and sensorineural hearing loss (SNHL), likely attributable to early life inflammation. Furthermore, we show that both immune cells and bone marrow hematopoietic progenitors can be simultaneously analyzed within neonatal cochlear samples. Future work investigating the pathogenesis of SNHL in the context of congenital infection will therefore provide critical information on how perinatal inflammation drives disease susceptibility in offspring.

show abstract

Section: The Cochlea As a Model Organ To Study The Effect Of Early Life Inflammation On The Developing Hematopoietic And Immune Systemsmentioning

confidence: 99%

Early Life Inflammation and the Developing Hematopoietic and Immune Systems: The Cochlea as a Sensitive Indicator of Disruption

Otsuka

Nielson

Firpo

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…A total of 14 reviews that assessed the safety of varicella vaccination did not specify the number of vaccine doses 23,25–32,35–39 . Two reviews that assessed the quadrivalent vaccine conducted a meta‐analysis, 29,32 while all other reviews provided a narrative synthesis of findings.…”

Section: Resultsmentioning

confidence: 99%

“…The fourth review noted international experience suggesting that febrile seizures are possible adverse effects of the quadrivalent MMRV vaccine 30 . A final review, assessing the safety of rubella‐containing vaccines, reported a single case of a 13 month old girl with high fever 1 day after MMRV vaccination and seizures 6 days later 38 …”

Section: Resultsmentioning

confidence: 99%

“…The majority of reviews had multiple methodological flaws with one review deemed ‘high’ quality, 32 two reviews deemed ‘low’ quality 23,37 and 14 reviews deemed ‘critically low’ quality 24–31,33–36,38,39 . None of the ‘critically low’ quality reviews included a protocol or explicit statement that the review methods were established prior to the conduct of the review.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety of varicella vaccination strategies: An overview of reviews

Ahern

Walsh

Paone

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

The safety of new vaccines under development as well as existing vaccines is a key priority for national and international public health agencies. A number of countries have implemented universal childhood varicella vaccination programmes over the past 30 years. However, strategies differ in terms of the number of doses, type of vaccine(s) recommended, age at vaccination and interval between doses for a twodose schedule. An overview of reviews was undertaken to assess the existing systematic review evidence of the safety of varicella vaccination strategies. The review was restricted to immunocompetent children aged 9 months to 6 years inclusive. A comprehensive search of databases, registries and grey literature was conducted up to 2 February 2022. Two reviewers independently screened, extracted data and assessed the methodological quality of included reviews. Overlap of included reviews was also assessed. A total of 17 reviews, incorporating both the monovalent varicella only and quadrivalent measles-mumps-rubella-varicella (MMRV) vaccines were included in the overview; six assessed the safety of one-dose strategies, four assessed the safety of two-dose strategies and 14 reviews did not specify the dosing strategy. The evidence suggests that mild local and systemic reactions are relatively common with varicella vaccination. Febrile seizures are also possible adverse effects of both the monovalent and quadrivalent MMRV vaccine, but serious adverse reactions are rare. While most reviews contained methodological flaws, and analysis by vaccine type and dosing strategy was restricted due to lack of detail in reporting of the reviews, there was clear and consistent evidence from a substantial evidence base, comprising 34 randomised controlled trials and 62 other primary studies/reviews, that varicella vaccination is safe.

show abstract

“…These findings resulted in this vaccine being accepted and used in almost all countries. A systematic literature review in 2019 showed that both single-dose and 2-dose regimens of rubella vaccine are highly immunogenic for a long period of time ( 26 ).…”

Section: Vaccine Selectionmentioning

confidence: 99%

Past as Prologue—Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination

Dixon¹,

Reef²,

Zimmerman³

et al. 2022

Emerg. Infect. Dis.

View full text Add to dashboard Cite

A s COVID-19 spreads throughout the world, we recall a similar experience of a swiftly spreading respiratory disease over half a century earlier. In 1963, a rubella virus epidemic spread from Europe to the United States, causing great alarm among public health officials. The New York Times reported on February 8, 1964: "GERMAN MEASLES AT EPI-DEMIC RATE; City and State Affected-2,302 Cases Reported Here Since Dec. 1; Virus Is Termed Mild; But Women Are Warned of Danger During First 3 Months of Pregnancy" (1).Although rubella is generally a mild disease, rubella infection during early pregnancy can be devastating. Fetal infection can result in miscarriage, stillbirth, or infants born with life-threatening or disabling congenital malformations, known as congenital rubella syndrome (CRS). A pregnant woman

show abstract

Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis

Cited by 11 publications

References 96 publications

Early Life Inflammation and the Developing Hematopoietic and Immune Systems: The Cochlea as a Sensitive Indicator of Disruption

Early Life Inflammation and the Developing Hematopoietic and Immune Systems: The Cochlea as a Sensitive Indicator of Disruption

Safety of varicella vaccination strategies: An overview of reviews

Past as Prologue—Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination

Contact Info

Product

Resources

About